Resources from the same session
277MO - SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
Presenter: Sarat Chandarlapaty
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
278MO - cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients
Presenter: Boris Krastev
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
279MO - Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016
Presenter: Suzette Delaloge
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
280MO - Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
Presenter: Pauline Corbaux
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
281MO - Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
Presenter: Marcela Carausu
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
282MO - Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial
Presenter: Xichun Hu
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
283MO - Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Presenter: Nicholas Turner
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA20 - Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Presenter: Robert Jones
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Laura Biganzoli
Session: Mini Oral - Breast cancer, metastatic
Resources:
Slides
Webcast
Invited Discussant 277MO and 278MO
Presenter: Francois-Clement Bidard
Session: Mini Oral - Breast cancer, metastatic
Resources:
Slides
Webcast